๐ฐ Mayo Collaborative Services News
Page 2 - Mayo Collaborative Services News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mayo Collaborative Services. Real-time updates on events, politics, business and more.
December 13, 2023
There may be some good news on the horizon for small business owners, courtesy of Congress.
December 6, 2023
America’s high-tech industries grew up hand in hand with a robust system of intellectual property rights. Without strong patent protections to encourage inventors, we would never have become a global
November 22, 2023
The Patent Eligibility Restoration Act would strengthen the U.S. intellectual property system, protect innovators, and shore up our ability to compete with geopolitical rivals.
October 24, 2023
Seemingly everyone is beginning to pay more attention to Washington’s efforts to regulate AI.
October 10, 2023
Recently, members of the Senate Judiciary Committeeโs Subcommittee on Intellectual Property released a draft of the โโPatent Eligibility Restoration Act of 2023โ (โPERAโ) for the purpose of addressing the judicially-created exceptions to patent eligibility plaguing the country.
October 9, 2023
This case addresses whether patents relating to methods and systems for connecting users based on their answers to polling questions claim patentable subject matter under 35 U.S.C. §...
October 6, 2023
In view of the unprecedented uncertainty in patent law generated by counter-doctrinal Supreme Court decisions over the past decade or so and a cowed Federal Circuit relegated to...
October 3, 2023
By Blake Brittain WASHINGTON (Reuters) - The U.S. Supreme Court on Monday declined to hear a lawsuit by CareDx over organ-rejection tests made by ...
October 2, 2023
The U.S. Supreme Court on Monday declined to hear a lawsuit by CareDx over organ-rejection tests made by Natera and Eurofins Viracor, turning down another request to revisit the contentious issue of...
October 2, 2023
WASHINGTON: The US Supreme Court on Monday declined to hear a lawsuit by CareDx over organ-rejection tests made by Natera and Eurofins Viracor, turning down another request to revisit the contentious issue of patent eligibility. The justices turned away CareDx's appeal of a lower court's ruling that invali